SV

Street Verdict

Analyst Scorecard

A record of what Sumeet Bagadia said publicly, with the source. Not advice.

“Bullish on Aurobindo Pharma, recommending a buy around ₹1158 with a stop-loss at ₹1117 for a target of ₹1240. The stock has rebounded from a key support zone, broken out of a falling trendline, and formed a Morning Star pattern, validated by rising volumes, signaling a potential trend reversal and renewed buying interest.”

Sumeet Bagadia’s track record (trackable calls only): 1528 graded calls · 95% CI 32–37%

Aurobindo Pharma Ltd.BullishCalled 03 Jul 2025Graded 22 Jul 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

Entry: ₹1,158, as stated.

Target ₹1,240, stop ₹1,117, as stated.

No time frame is stated, so it is tracked until a close reaches ₹1,240 or ₹1,117: there is no fixed window.

The stop ₹1,117 was reached on a close before the target ₹1,240. Miss.

The grader’s working: R3 TRADE_SETUP: entered ₹1158 on 2025-07-04 (stated entry ₹1158, LEVEL_CMP entry, filled); stop ₹1117 breached at close ₹1101.4 on 2025-07-22. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

Tracking Aurobindo Pharma Ltd. since this call

1-year tracking window
Read the original articleSee Sumeet Bagadia’s full track record